Debevoise Advises Allergan in Collaboration Deal with AstraZeneca to Develop and Commercialize ATM-AVI

29 January 2016

Debevoise & Plimpton LLP is advising Allergan plc in its global collaboration agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Both companies will evaluate the combination to treat the most serious infections caused by multi-drug-resistant pathogens, including infections for which there are currently very limited treatments. Under the terms of the agreement, Allergan will maintain commercialization rights in the U.S. and Canada and AstraZeneca will maintain commercialization rights in all other countries.

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model—Growth Pharma. Allergan is focused on developing, manufacturing, and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines, and biologic products for patients around the world.

The Debevoise team is led by partner Jennifer L. Chu and includes partner Andrew L. Bab and associate Vincent J. Bianco.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.